Helius Medical Technologies Announces Publication of Positive Results of Russian Pediatric Cerebral Palsy Pilot Study
Researchers Concluded Facilitation of Physiotherapy With the Investigational PoNS™ Device has an Ability to Improve Motor Control in Pediatric Patients With Cerebral Palsy
Results Accepted for Publication and Scheduled for Presentation
NEWTOWN, PENNSYLVANIA--(Marketwired - Sept. 6, 2016) - Helius Medical Technologies, Inc. (TSX:HSM)(OTCQB:HSDT) ("Helius" or the "Company") announces that results from a pilot study, investigating the benefits of PoNS™ technology with physiotherapy in treating symptoms of pediatric Cerebral Palsy (CP), have been accepted for publication in the Russian "Journal of Restorative Medicine and Rehabilitation" (vvmr.ru/). Results of the study will be presented in an oral session at the International Conference for Innovation in Angio-Neurology held in Moscow on September 23-24, 2016 (altaastra.com/2016/07/angioneurology), a gathering of more than 500 neurologists, neurosurgeons, trauma doctors and other healthcare practitioners. The PoNS™ is an investigational device that is currently in clinical development in the United States and has not been cleared for commercial distribution.
This 65-subject (45-active, 20 control) study included children (ages 3-13) with Gross Motor Function Classification Scores (GMFCS) ranging from II-IV*. All subjects received 10-days of standard physiotherapy and movement control therapy with the active group receiving 20-25 minutes of concomitant electro-lingual neurostimulation with PoNS™. Primary outcomes were scored by Ashworth Scale (spasticity), Berg Scale (Balance) and GMFCS. Secondary measures included preferred walking speed, step length, lower extremity strength and quality of life measures. Statistically significant differences in spasticity (p< 0.005) and lower limb gross motor function (p